Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Xuezhikang therapy increases miR-33 expression in patients with low HDL-C levels.

Cao R, Bai Y, Sun L, Zheng J, Zu M, Du G, Ye P.

Dis Markers. 2014;2014:781780. doi: 10.1155/2014/781780. Epub 2014 Jan 23.

2.

Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age.

Martino F, Carlomosti F, Avitabile D, Persico L, Picozza M, Barillà F, Arca M, Montali A, Martino E, Zanoni C, Parrotto S, Magenta A.

Clin Sci (Lond). 2015 Dec;129(11):963-72. doi: 10.1042/CS20150235. Epub 2015 Jul 30.

PMID:
26229086
3.

Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.

Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ, Brusco OA, Lu G, Lerman S, Duan Z, Guo S, Liu PL, Zhao J, Zhang Y, Li S.

J Clin Lipidol. 2014 Nov-Dec;8(6):568-75. doi: 10.1016/j.jacl.2014.09.002. Epub 2014 Sep 16.

PMID:
25499939
4.

Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides.

Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, Khatsenko OG, Kaimal V, Lees CJ, Fernandez-Hernando C, Fisher EA, Temel RE, Moore KJ.

Nature. 2011 Oct 19;478(7369):404-7. doi: 10.1038/nature10486.

5.

Effects of withdrawal of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with coronary artery disease.

Hu CL, Li YB, Tang YH, Chen JB, Liu J, Tang QZ, Zhang QH, Huang CX.

Cardiovasc Drugs Ther. 2006 Jun;20(3):185-91.

PMID:
16775668
6.

[Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].

Jiang FY, Sun LP, Yang J.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Dec;31(12):1607-10. Chinese.

PMID:
22384544
7.

MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo.

Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, Usami S, Izuhara M, Nakazeki F, Ide Y, Koyama S, Sowa N, Yahagi N, Shimano H, Nakamura T, Hasegawa K, Kume N, Yokode M, Kita T, Kimura T, Ono K.

Sci Rep. 2014 Jun 16;4:5312. doi: 10.1038/srep05312.

8.

Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease.

Gao W, He HW, Wang ZM, Zhao H, Lian XQ, Wang YS, Zhu J, Yan JJ, Zhang DG, Yang ZJ, Wang LS.

Lipids Health Dis. 2012 May 15;11:55. doi: 10.1186/1476-511X-11-55.

9.

Dialysis method alters the expression of microRNA-33a and its target genes ABCA1, ABCG1 in THP-1 macrophages.

Wang JM, Zhou JJ, Zheng Q, Gan H, Wang H.

Ther Apher Dial. 2014 Feb;18(1):44-50. doi: 10.1111/1744-9987.12040.

PMID:
24499083
10.

Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia.

Ding M, Si D, Zhang W, Feng Z, He M, Yang P.

Exp Ther Med. 2014 Dec;8(6):1737-1744. Epub 2014 Oct 21.

12.

Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.

Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM; Chinese Coronary Secondary Prevention Study Group, Li S.

Am J Cardiol. 2008 Jun 15;101(12):1689-93. doi: 10.1016/j.amjcard.2008.02.056. Epub 2008 Apr 11.

PMID:
18549841
13.

MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer.

Wolfe AR, Bambhroliya A, Reddy JP, Debeb BG, Huo L, Larson R, Li L, Ueno NT, Woodward WA.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):791-9. doi: 10.1016/j.ijrobp.2016.01.025. Epub 2016 Jan 22.

PMID:
27055396
14.
15.

[Effects of Xuezhikang on serum levels of high sensitive-C reactive protein, matrix metalloproteinase-9 and lipoprotein in patients with acute coronary syndrome].

Huang J, Wang MH, Peng XP, Wei C, Lu J.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Mar;26(3):221-3. Chinese.

PMID:
16613266
16.

miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling.

Dávalos A, Goedeke L, Smibert P, Ramírez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC, Esplugues E, Fisher EA, Penalva LO, Moore KJ, Suárez Y, Lai EC, Fernández-Hernando C.

Proc Natl Acad Sci U S A. 2011 May 31;108(22):9232-7. doi: 10.1073/pnas.1102281108. Epub 2011 May 16.

17.

Chronic administration of proanthocyanidins or docosahexaenoic acid reverses the increase of miR-33a and miR-122 in dyslipidemic obese rats.

Baselga-Escudero L, Arola-Arnal A, Pascual-Serrano A, Ribas-Latre A, Casanova E, Salvadó MJ, Arola L, Blade C.

PLoS One. 2013 Jul 26;8(7):e69817. doi: 10.1371/journal.pone.0069817. Print 2013.

18.

Analysis of circulating microRNAs that are specifically increased in hyperlipidemic and/or hyperglycemic sera.

Simionescu N, Niculescu LS, Sanda GM, Margina D, Sima AV.

Mol Biol Rep. 2014 Sep;41(9):5765-73. doi: 10.1007/s11033-014-3449-2. Epub 2014 Jun 14.

PMID:
24928089
20.

Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension.

Lu L, Zhou JZ, Wang L, Zhang TX.

Chin J Integr Med. 2009 Aug;15(4):266-71. doi: 10.1007/s11655-009-0266-x. Epub 2009 Aug 18.

PMID:
19688314
Items per page

Supplemental Content

Write to the Help Desk